



**Our STN: BL 125681/29**

**SUPPLEMENT APPROVAL**  
**January 8, 2025**

Abbott GmbH  
Attention: Mark Paradowski  
Abbott Laboratories  
Dept. T3M2, Bldg. AP20  
100 Abbott Park Road  
Abbott Park, IL 60064

Dear Mark Paradowski:

We have approved your request received July 19, 2024, to supplement your Biologics License Applications (BLA) submitted under section 351(a) of the Public Health Service Act, for the biological product for Hepatitis B Virus Core Antigen (*E coli*, Recombinant) to update the labeling for the Alinity s Anti-HBc to reflect hazard content included in the current hazard evaluation, as well as for administrative and alignment purposes.

We hereby approve the draft package insert labeling submitted with the supplement, received July 19, 2024. This is a reminder that as of September 24, 2014, medical devices that are licensed under the PHS Act are subject to certain provisions of the final Unique Device Identifier (UDI) rule. These provisions include the requirement to provide a UDI on the device label and packages (21 CFR 801.20), format dates on the device label in accordance with 21 CFR 801.18 and submit data to the Global Unique Device Identification Database (GUDID) (21 CFR 830 Subpart E). Additionally, please identify each device identifier implemented for the subject device, and the device identifiers that have been discontinued for the subject device as a labeling change in an annual report consistent with 21 CFR 601.12(f)(3). For more information on these requirements, please see the UDI website at <http://www.fda.gov/udi>.

Please submit all final printed labeling as PDF electronic copy (eCopy) at the time of use and include implementation information on Form FDA 356h as appropriate.

Two draft copies of the proposed introductory advertising or promotional labeling may be voluntarily submitted for advisory comment with a completed Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address, unless otherwise specified:

Food and Drug Administration  
Center for Biologics Evaluation and Research  
Document Control Center  
10903 New Hampshire Ave.  
WO71–G112  
Silver Spring, MD 20993-0002

We will include the information contained in the above-referenced supplements in your BLA files.

Sincerely,

Hira L. Nakhasi, PhD  
Director  
Division of Emerging and  
Transfusion Transmitted Diseases  
Office of Blood Research and Review  
Center for Biologics Evaluation and Research